Clinical/demographic characteristics of the participants included in the analysis
| . | War-PATH cohort 1 (N = 548) . | War-PATH cohort 2 (N = 214) . | War-PATH cohort 3 (N = 133) . | War-PATH cohort 4 (N = 94) . | IWPC cohort (N = 316) . | UAB cohort (N = 199) . | Overall (N = 1504) . |
|---|---|---|---|---|---|---|---|
| Age (y) | |||||||
| Mean (SD) | 46.4 (15.7) | 49.0 (16.0) | 60.1 (14.9) | 49.3 (17.0) | 57.0 (14.7) | 58.9 (15.3) | 52.1 (16.4) |
| Median [Q1, Q2] | 45.6 [34.8, 57.0] | 48.0 [37.0, 60.8] | 62.0 [53.0, 71.0] | 49.0 [36.0, 63.0] | 58.0 [48.0, 67.0] | 60.0 [48.0, 72.0] | 52.0 [40.0, 64.0] |
| Weight (kg)∗ | |||||||
| Mean (SD) | 75.1 (20.0) | 73.3 (18.0) | 77.1 (18.2) | 74.8 (18.6) | 93.9 (26.6) | 67.3 (4.08) | 77.9 (21.6) |
| Median [Q1, Q2] | 71.4 [60.0, 86.0] | 70.0 [60.0, 82.0] | 74.0 [62.8, 92.0] | 72.0 [61.0, 83.8] | 91.8 [75.0, 107.0] | 67.0 [64.0, 71.0] | 72.0 [63.0, 90.0] |
| Sex | |||||||
| Female | 390 (71.2%) | 160 (74.8%) | 87 (65.4%) | 39 (41.5%) | 199 (63.0%) | 109 (54.8%) | 984 (65.4%) |
| Male | 158 (28.8%) | 54 (25.2%) | 46 (34.6%) | 55 (58.5%) | 117 (37.0%) | 90 (45.2%) | 520 (34.6%) |
| Ancestry proportions,† mean (SD) | |||||||
| African | 97.1% (3.4%) | 98.6% (2.7%) | 35.1% (19.2%) | 83.1% (3.0%) | 82.6% (9.2%) | 83.7% (7.8%) | 86.1% (19.1%) |
| East Asian | 0.2% (0.2%) | 0.1% (0.1%) | 13.2% (8.4%) | 2.6% (0.8%) | - | - | 1.4% (4.5%) |
| European | 2.2% (2.7%) | 1.1% (2%) | 30.2% (14.2%) | 8.8% (1.9%) | 17.4% (9.2%) | 16.3% (7.8%) | 10.0% (11.5%) |
| South Asian | 0.5% (0.8%) | 0.3% (0.9%) | 21.5% (10.9%) | 5.4% (1.8%) | - | - | 2.5% (6.9%) |
| Target INR range‡ | |||||||
| 2.0-3.0 | 357 (65.1%) | 163 (76.2%) | 82 (61.7%) | 87 (92.6%) | 285 (90.2%) | 199 (100%) | 1173 (78.0%) |
| 2.5-3.5 | 191 (34.9%) | 51 (23.8%) | 51 (38.3%) | 7 (7.4%) | 31 (9.8%) | 0 (0%) | 331 (22.0%) |
| On simvastatin/amiodarone | |||||||
| No | 497 (90.7%) | 208 (97.2%) | 86 (64.7%) | 84 (89.4%) | 238 (75.3%) | 192 (96.5%) | 1305 (86.8%) |
| Yes | 51 (9.3%) | 6 (2.8%) | 47 (35.3%) | 10 (10.6%) | 78 (24.7%) | 7 (3.5%) | 199 (13.2%) |
| Weekly dose (mg) | |||||||
| Mean (SD) | 41.2 (18.5) | 36.4 (14.7) | 35.2 (15.4) | 34.3 (11.9) | 45.5 (18.7) | 42.4 (18.6) | 40.6 (17.8) |
| Median [Q1, Q2] | 35.0 [30.0, 50.0] | 35.0 [27.5, 42.5] | 32.5 [25.0, 45.0] | 32.5 [27.5, 37.5] | 42.0 [32.5, 55.1] | 40.0 [27.5, 50.0] | 35.0 [30.0, 50.0] |
| . | War-PATH cohort 1 (N = 548) . | War-PATH cohort 2 (N = 214) . | War-PATH cohort 3 (N = 133) . | War-PATH cohort 4 (N = 94) . | IWPC cohort (N = 316) . | UAB cohort (N = 199) . | Overall (N = 1504) . |
|---|---|---|---|---|---|---|---|
| Age (y) | |||||||
| Mean (SD) | 46.4 (15.7) | 49.0 (16.0) | 60.1 (14.9) | 49.3 (17.0) | 57.0 (14.7) | 58.9 (15.3) | 52.1 (16.4) |
| Median [Q1, Q2] | 45.6 [34.8, 57.0] | 48.0 [37.0, 60.8] | 62.0 [53.0, 71.0] | 49.0 [36.0, 63.0] | 58.0 [48.0, 67.0] | 60.0 [48.0, 72.0] | 52.0 [40.0, 64.0] |
| Weight (kg)∗ | |||||||
| Mean (SD) | 75.1 (20.0) | 73.3 (18.0) | 77.1 (18.2) | 74.8 (18.6) | 93.9 (26.6) | 67.3 (4.08) | 77.9 (21.6) |
| Median [Q1, Q2] | 71.4 [60.0, 86.0] | 70.0 [60.0, 82.0] | 74.0 [62.8, 92.0] | 72.0 [61.0, 83.8] | 91.8 [75.0, 107.0] | 67.0 [64.0, 71.0] | 72.0 [63.0, 90.0] |
| Sex | |||||||
| Female | 390 (71.2%) | 160 (74.8%) | 87 (65.4%) | 39 (41.5%) | 199 (63.0%) | 109 (54.8%) | 984 (65.4%) |
| Male | 158 (28.8%) | 54 (25.2%) | 46 (34.6%) | 55 (58.5%) | 117 (37.0%) | 90 (45.2%) | 520 (34.6%) |
| Ancestry proportions,† mean (SD) | |||||||
| African | 97.1% (3.4%) | 98.6% (2.7%) | 35.1% (19.2%) | 83.1% (3.0%) | 82.6% (9.2%) | 83.7% (7.8%) | 86.1% (19.1%) |
| East Asian | 0.2% (0.2%) | 0.1% (0.1%) | 13.2% (8.4%) | 2.6% (0.8%) | - | - | 1.4% (4.5%) |
| European | 2.2% (2.7%) | 1.1% (2%) | 30.2% (14.2%) | 8.8% (1.9%) | 17.4% (9.2%) | 16.3% (7.8%) | 10.0% (11.5%) |
| South Asian | 0.5% (0.8%) | 0.3% (0.9%) | 21.5% (10.9%) | 5.4% (1.8%) | - | - | 2.5% (6.9%) |
| Target INR range‡ | |||||||
| 2.0-3.0 | 357 (65.1%) | 163 (76.2%) | 82 (61.7%) | 87 (92.6%) | 285 (90.2%) | 199 (100%) | 1173 (78.0%) |
| 2.5-3.5 | 191 (34.9%) | 51 (23.8%) | 51 (38.3%) | 7 (7.4%) | 31 (9.8%) | 0 (0%) | 331 (22.0%) |
| On simvastatin/amiodarone | |||||||
| No | 497 (90.7%) | 208 (97.2%) | 86 (64.7%) | 84 (89.4%) | 238 (75.3%) | 192 (96.5%) | 1305 (86.8%) |
| Yes | 51 (9.3%) | 6 (2.8%) | 47 (35.3%) | 10 (10.6%) | 78 (24.7%) | 7 (3.5%) | 199 (13.2%) |
| Weekly dose (mg) | |||||||
| Mean (SD) | 41.2 (18.5) | 36.4 (14.7) | 35.2 (15.4) | 34.3 (11.9) | 45.5 (18.7) | 42.4 (18.6) | 40.6 (17.8) |
| Median [Q1, Q2] | 35.0 [30.0, 50.0] | 35.0 [27.5, 42.5] | 32.5 [25.0, 45.0] | 32.5 [27.5, 37.5] | 42.0 [32.5, 55.1] | 40.0 [27.5, 50.0] | 35.0 [30.0, 50.0] |
MICE, multivariate imputation by chained equations; N, sample size; Q1, first quartile; Q2, second quartile; SD, standard deviation; War-PATH cohort 4, mixed ancestry and Black Africans recruited from Uganda and South Africa.
11 (2.0%), 1 (0.5%), and 7 (5.3%) participants were missing weight information in War-PATH cohorts 1 (Black Africans recruited from Uganda and South Africa), 2 (Black Africans from South Africa and Zimbabwe), and 3 (mixed ancestry South African participants), respectively, which was singly imputed using the MICE R package.
Two and 4 reference populations used for the African American and sub-Saharan African cohorts, respectively.
Those with heart valve disorders have a higher target range (2.5-3.5) than the rest (2.0-3.0) who mostly include those with atrial fibrillation and venous thromboembolism.